 |
|
|
| |
Week 48 efficacy analysis of the PROTEA trial:
darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL at baseline
|
| |
| |
Reported by Jules Levin
HIV Drug Therapy Conference, Glasgow, UK, November 2014
1Andrea Antinori, National Institute of Infectious Diseases, Infectious Diseases, Rome, Italy 2. Jose Arribas, Hospital la Paz, IdiPAZ, Madrid, Spain 3. Jan Fehr, University Hospital, Zurich, Switzerland 4. Pierre-Marie Girard, Hopital Saint-Antoine, Paris, France 5. Andrzej Horban, Warsaw Medical University, Poland 6. Andrew Hill, Janssen, R&D, High Wycombe, United Kingdom 7. Yvon van Delft, Janssen, EMEA, Tilburg, Netherlands 8. Christiane Moecklinghoff, Janssen, EMEA, Neuss, Germany
|
| |
|
|
|
|
|
